Morgan Stanley analyst Mark Purcell raised the firm’s price target on Novartis to CHF 91 from CHF 88 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis price target raised to CHF 85 from CHF 80 at Barclays
- Pharming Novartis announces first commercial shipments of Joenja in U.S.
- TD Cowen pharmaceuticals analysts to hold analyst/industry conference call
- Novartis’ Sandoz announces EC approval for HCF Hyrimoz
- Novartis’ Entresto receives positive CHMP opinion for pediatric heart failure